Research programme: stereopure nucleic acid therapeutics - WaVe Life Sciences

Drug Profile

Research programme: stereopure nucleic acid therapeutics - WaVe Life Sciences

Alternative Names: ApoC-III modulators - WAVE Life Sciences; Apolipoprotein C-III modulators - WaVe Life Sciences; Exon 51 modulators - WaVe Life Sciences; WVE-210201

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator WaVe life Sciences
  • Developer Pfizer; University of Dundee; University of Massachusetts Medical School; University of Oxford; WaVe life Sciences
  • Class Anti-inflammatories; Antisense elements; Apolipoprotein therapeutics; Eye disorder therapies; Neuroprotectants; Nucleic acids; Skin disorder therapies
  • Mechanism of Action Apolipoprotein C-III modulators; Dystrophin expression stimulants; Gene expression modulators; RNA interference; Smad7 protein modulators; Survival of motor neuron 2 protein expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • Research Amyotrophic lateral sclerosis; Epidermolysis bullosa; Eye disorders; Inflammatory bowel diseases; Liver disorders; Metabolic disorders; Myotonic dystrophy; Skin disorders; Spinal muscular atrophy

Most Recent Events

  • 08 Jun 2017 ReadCoor and WAVE Life Sciences initiate a research collaboration to charecterise and advance WAVE’s stereopure nucleic acid candidates
  • 10 May 2017 WAVE Life Sciences plans clinical trials of WVE 120101 and WVE 120102 for Huntington's disease in mid 2017
  • 10 May 2017 Wave Life Sciences plans clinical trials of WVE 210201 for Duchenne Muscular Dystrophy in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top